Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Pharmacological Research

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.PHRS.2007.01.020PMID 17349798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drugs for Increasing Oxygen Transport and Their Potential Use in Doping

  2012cited by this paper
• Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

  2007cited by this paper
• Interaction of IGF signaling and the androgen receptor in prostate cancer progression

  2006cited by this paper
• Erythropoietin Biology in Cancer

  2006cited by this paper
• The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands

  2006cited by this paper
• Human growth hormone doping in sport

  2006influential reference
• Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

  2006cited by this paper
• Molecular regulation of androgen action in prostate cancer

  2006cited by this paper
• Anti-Epo receptor antibodies do not predict Epo receptor expression.

  2006influential reference
• Growth hormone and cancer: are we asking the right questions? *

  2006cited by this paper
• Circulating Steroid Hormones and the Risk of Prostate Cancer

  2006cited by this paper
• The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

  2006cited by this paper
• Popular Ergogenic Drugs and Supplements in Young Athletes

  2006cited by this paper
• Anabolic Steroids: A Fatal Attraction?

  2006cited by this paper
• Does growth hormone cause cancer?

  2006cited by this paper
• Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

  2006influential reference
• Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors*

  2006cited by this paper
• Does growth hormone therapy increase the risk of cancer?

  2006cited by this paper
• Gene Therapy Progress and Prospects: Development of improved lentiviral and retroviral vectors – design, biosafety, and production

  2005cited by this paper
• Co‐operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor

  2005cited by this paper
• Pharmacoepidemiology of anabolic androgenic steroids: a review

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• GH Receptor Antagonist: Mechanism of Action and Clinical Utility

  2005cited by this paper
• Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.

  2005cited by this paper
• Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature

  2005cited by this paper
• Role of insulin-like growth factor 1 receptor signalling in cancer

  2005cited by this paper
• Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

  2005cited by this paper
• Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC)

  2005cited by this paper
• The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

  2005cited by this paper
• Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling

  2005cited by this paper
• Growth hormone abuse: methods of detection.

  2005cited by this paper
• Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

  2005cited by this paper
• Sex Hormone-Induced Mammary Carcinogenesis in Female Noble Rats: Detection of Differentially Expressed Genes

  2004cited by this paper
• Evidence for a link between IGF-I and cancer.

  2004cited by this paper
• The role of erythropoietin in regulating angiogenesis.

  2004cited by this paper
• Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy.

  2004cited by this paper
• Androgens and liver tumors: Fanconi's anemia and non‐Fanconi's conditions

  2004cited by this paper
• Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients.

  2004cited by this paper
• Structure-activity comparison of organotin species: dibutyltin is a developmental neurotoxicant in vitro and in vivo.

  2004cited by this paper
• The Wnt signaling pathway in development and disease.

  2004cited by this paper
• Ergogenic aids: Human growth hormone

  2004cited by this paper
• Insulin-like growth factors and neoplasia.

  2004cited by this paper
• The insulin-like growth factor system in advanced breast cancer.

  2004cited by this paper
• Insulin-like growth factors and neoplasia

  2004influential reference
• Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland*

  2004cited by this paper
• Impact of dehydroepiandrosterone on hepatocarcinogenesis in the rat (Review).

  2004cited by this paper
• Androgen receptor in prostate cancer.

  2004cited by this paper
• Erythropoietin regulates tumour growth of human malignancies.

  2003cited by this paper
• A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

  2003cited by this paper
• Peptide and glycoprotein hormones and sport

  2003cited by this paper
• Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.

  2003cited by this paper
• Drugs for increasing oxygen and their potential use in doping: a review.

  2003cited by this paper
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

  2003cited by this paper
• The GH-IGF-I axis and breast cancer.

  2003cited by this paper
• LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1

  2003cited by this paper
• Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.

  2003influential reference
• Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.

  2002cited by this paper
• Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study.

  2002cited by this paper
• Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines.

  2002cited by this paper
• Steroid Use and Long-Term Health Risks in Former Athletes

  2002cited by this paper
• Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells*

  2002cited by this paper
• Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells.

  2002cited by this paper
• Clinical perspective: acromegaly and cancer: a problem.

  2001cited by this paper
• Insulin, growth hormone and sport.

  2001cited by this paper
• Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist

  2001cited by this paper
• Drugs in sport - the role of the physician.

  2001cited by this paper
• Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. final results of a randomized phase III study

  2001cited by this paper
• Increased premature mortality of competitive powerlifters suspected to have used anabolic agents.

  2000cited by this paper
• Growth hormone and sport

  2000cited by this paper
• Role of the insulin-like growth factor family in cancer development and progression.

  2000cited by this paper
• Experimental prostate carcinogenesis - rodent models.

  2000cited by this paper
• Erythropoietin Stimulates Proliferation and Interferes with Differentiation of Myoblasts*

  2000cited by this paper
• Drug use and abuse in sport.

  2000cited by this paper
• Blood boosting and sport.

  2000cited by this paper
• Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder.

  2000cited by this paper
• Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation

  2000cited by this paper
• Intratesticular leiomyosarcoma in a young man after high dose doping with oral‐turinabol

  2000cited by this paper
• Use of recombinant human erythropoietin as an antianemic and performance enhancing drug.

  2000cited by this paper
• Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction.

  1999cited by this paper
• Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3

  1999cited by this paper
• Effects of erythropoietin administration in training athletes and possible indirect detection in doping control.

  1999cited by this paper
• Intratesticular leiomyosarcoma in a young man after high dose doping with oral‐turinabol

  1999cited by this paper
• Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

  1999cited by this paper
• Regulation of the erythropoietin gene.

  1999influential reference
• Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).

  1999cited by this paper
• Anabolic steroid abuse and renal cell carcinoma.

  1999cited by this paper
• Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

  1999cited by this paper
• Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function.

  1998cited by this paper
• Jak2 is essential for signaling through a variety of cytokine receptors.

  1998cited by this paper
• Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.

  1998cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• In vivo evidence that erythropoietin protects neurons from ischemic damage.

  1998cited by this paper
• Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I.

  1998cited by this paper
• Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents.

  1998cited by this paper
• Exposure to anabolic-androgenic steroids shortens life span of male mice.

  1997cited by this paper
• Adolescents and anabolic steroids: a subject review. American Academy of Pediatrics. Committee on Sports Medicine and Fitness.

  1997cited by this paper
• The androgen receptor in prostate cancer.

  1996cited by this paper
• Androgen use by athletes: a reevaluation of the health risks.

  1996cited by this paper

• Testosterone replacement therapy and bladder cancer.

  2025cites this paper
• Schäden bei Dopingopfern der DDR

  2024cites this paper
• Excessive androgen exposure and risk of malignancies: A cohort study

  2024cites this paper
• [Changes in motor unit activity in the biceps brachii muscle under different intensities of isometric loading].

  2023cites this paper
• Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target

  2023cites this paper
• Sport et dopage

  2022cites this paper
• Effectiveness of anabolic steroids in improving outcomes for post-operative hip fracture patients: A randomized controlled trial.

  2022cites this paper
• Prevention Effect of News Shocks in Anti-Doping Policies

  2021cites this paper
• Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review

  2021cites this paper
• IGF-1R Transported to the Cell Nuclei to Regulate the Proliferation of Breast Cancer Cells

  2021cites this paper
• Doping stigmata as pathological clinical signs in the diagnostic field of sports anthropology

  2020cites this paper
• Nandrolone Decanoate: Use, Abuse and Side Effects

  2020cites this paper
• Medicina del deporte

  2019cites this paper
• Enhancing detectability of anabolic-steroid residues in bovine urine by actively modulated online comprehensive two-dimensional liquid chromatography - high-resolution mass spectrometry.

  2018cites this paper
• Can Plasma Rich in Growth Factors Be Safe for Parental Use? A Safety Study in the Canine Model

  2018cites this paper
• Dope in sport as research topic (Russian contributions review)

  2018cites this paper
• Evidence to inform the inclusion of Schedule 4 prescription medications on a real-time prescription monitoring system

  2017cites this paper
• Gene and Cell Doping: The New Frontier - Beyond Myth or Reality.

  2017cites this paper
• Serum reference value of two potential doping candidates—myostatin and insulin-like growth factor-I in the healthy young male

  2017cites this paper
• Equine performance genes and the future of doping in horseracing.

  2017cites this paper
• Sport und Krebsprävention

  2017cites this paper
• Doping in sport and exercise: anabolic, ergogenic, health and clinical issues

  2016influential citation
• effect of genF20 Plus on serum igF-1 levels in healthy adults: a randomized controlled study

  2015cites this paper
• Psychological and social correlates of doping attitudes among Italian athletes.

  2015cites this paper
• Morphometric effects of testosterone supplementation on certain extremity bones in young swim-trained rats

  2015cites this paper
• Chromosome Damage, Apoptosis, and Necrosis in Exfoliated Cells of Oral Mucosa From Androgenic Anabolic Steroids Users

  2015cites this paper
• Effect of GenF20 Plus on serum IGF-1 levels in healthy adults: a randomized controlled study

  2015cites this paper
• GENE DOPING IN SPORT – PERSPECTIVES AND RISKS

  2014cites this paper
• Currently neglected, physical examination maintains its clinical relevance

  2014cites this paper
• Influencia de administración de eritropoyetina humana recombinante en el rendimiento físico: un estudio de revisión

  2014cites this paper
• Creating fear: The social construction of human Growth Hormone as a dangerous doping drug

  2013influential citation
• The Effects of Mechanical Loading on Tendons - An In Vivo and In Vitro Model Study

  2013cites this paper
• The adverse health consequences of the use of multiple performance-enhancing substances--a deadly cocktail.

  2013cites this paper
• Darbepoetin inhibits proliferation of hepatic cancer cells in the presence of TGF-β

  2013cites this paper
• A perspective on the role of estrogen in hormone-induced prostate carcinogenesis.

  2013cites this paper
• Avaliação da ocorrência de danos cromossômicos, apoptose e necrose em células esfoliadas da mucosa oral de usuários de esteróides anabolizantes androgênicos

  2013cites this paper
• Obesity‐related colon cancer: Dietary factors and their mechanisms of anticancer action ‡

  2012cites this paper
• Insulin and Insulin‐Like Growth Factor

  2012cites this paper
• Justifying anti-doping: The fair opportunity principle and the biology of performance enhancement

  2012cites this paper
• Does single intramuscular application of autologous conditioned plasma influence systemic circulating growth factors?

  2012cites this paper
• The androgenic anabolic steroid tetrahydrogestrinone produces dioxin-like effects via the aryl hydrocarbon receptor.

  2012cites this paper
• Czy suplementacja argininą jest skuteczną metodą wspomagania zdolności wysiłkowych w sporcie

  2011cites this paper
• Changes in the miRNA profile under the influence of anabolic steroids in bovine liver.

  2011cites this paper
• A large fibrolamellar hepatocellular carcinoma in a 17-year-old male body builder.

  2011cites this paper
• Influence of anabolic combinations of an androgen plus an estrogen on biochemical pathways in bovine uterine endometrium and ovary.

  2011cites this paper
• Hormones and prostate carcinogenesis: Androgens and estrogens

  2011cites this paper
• Doping and musculoskeletal system: short‐term and long‐lasting effects of doping agents

  2011cites this paper
• Influence of Intramuscular Application of Autologous Conditioned Plasma on Systemic Circulating IGF-1.

  2011cites this paper
• Impact of physical activity and doping on epigenetic gene regulation.

  2011cites this paper
• Why are we losing the war against doping? In fact, do we want to win at all?

  2011cites this paper
• Characterization of the equine skeletal muscle transcriptome identifies novel functional responses to exercise training

  2010cites this paper
• The Use of Soluble Transferrin Receptor in the Detection of rHuEPO abuse in Sports

  2010cites this paper
• The Effects of Growth Hormone and Insulin-Like Growth Factor-1 Treatments on Hepatic Gene Expression in Obese and Diabetic Mice with Nonalcoholic Fatty Liver Disease

  2010cites this paper
• Biomedisinsk teknologi i idrett: hvor går grensene?

  2010cites this paper
• Dietary Fat, Fiber, and Carbohydrate Intake and Endogenous Hormone Levels in Premenopausal Women

  2010influential citation
• Gene doping.

  2010cites this paper
• History of Sports Drug Testing

  2010cites this paper
• In vitro lectin-mediated selection and characterization of rHuEPO-α-binding ssDNA aptamers.

  2010cites this paper
• Anabolic steroids: A review of the literature

  2009cites this paper
• Endocrinological derangements in COPD

  2009cites this paper
• [Growth hormone and IGF-1 as doping agents in competitive sport].

  2009cites this paper
• Salivary free Insulin-like Growth Factor-I levels: Effects of an acute physical exercise in athletes

  2009cites this paper
• Anabolic-androgenic steroid users in treatment : social background, drug use patterns, and criminality

  2009cites this paper
• Foie et sport

  2008cites this paper
• Age-related decline in immunity: implications for vaccine responsiveness

  2008cites this paper
• [Liver and sport].

  2008cites this paper
• Journal of the International Society of Sports Nutrition Open Access a League of Their Own: Demographics, Motivations and Patterns of Use of 1,955 Male Adult Non-medical Anabolic Steroid Users in the United States

  2007cites this paper
• Characterization of Value Nutritions 5-Androstenediol Product and its Proliferative Effects on the LNCaP Cell Line

  2007influential citation
• NOVEL ERYTHROPOIETIC AGENTS: A THREAT TO SPORTSMANSHIP

  2007cites this paper